Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
going to be fewer after the reverse split.
Nice. Happy I'm still sitting on a few shares here
Any ideas on snta?
Ya, the ask pps has been low. I'm out as of today. Made money so can't complain. Good luck to all.
IMO, Bid support not good...deceiving. I'd rather see big numbers on the Ask.
Nevertheless, this stock is trash.
It wants to move up, but keeps getting knocked down on low volume. I think there is a heavy short presence again trying to keep it down. Bid support still looking strong.
Imo
24 must hold otherwise IMO it'll drop back to 22.
Figured this would happen, most of the upcoming catalyst have been terminated and management made no guarantees regarding investor allocation of the remaining cash.
On SNTA 1 min Chart .24 Cents key support so let's see what happens
Profit taking from our recent drop to 22/23.
This typically only moves up 2 days before 1 day red. 2 up 1 down with the general trend still moving up.
Imo
SNTA low volume Drop of 10%, going lower?
Hope Drug Trial Results are not in Play.
I sent synta Parm. an email inquiring about clinical trial results!
I sent synta Parm. an email inquiring about clinical trial results!
Love to see this bust through .30 tomorrow in a BIG way!!!!
Go SNTA
Strong day. I saw some pretty big bids popping up towards end of day as well. I could not find any new information beyond the last 10k, other than buyout rumors.
Imo
board is quiet after a day like today........interesting
Don't know if this is fresh News or not but this was released at 1:04 PM today according to yahzoo:
SNTA SYNTA PHARMACEUTICALS CORP Financials at EDGAR Online
Financials Fri 1:04pm
http://finance.yahoo.com/q/is?s=snta
Good weekend to all. dp
Only 98k volume AH, sure it's nothing
? I will take it......
I'm checking for a Friday after hour PR
$SNTA recent news/filings
bullish 0.239
## source: finance.yahoo.com
$SNTA charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SNTA company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SNTA/company-info
Ticker: $SNTA
OTC Market Place: Not Available
CIK code: 0001157601
Company name: Synta Pharmaceuticals, Inc.
Incorporated In:
$SNTA share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$SNTA extra dd links
Company name: Synta Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SNTA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SNTA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SNTA+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/news - http://finance.yahoo.com/q/h?s=SNTA+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SNTA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SNTA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SNTA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Synta+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Synta+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Synta+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SNTA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157601&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SNTA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SNTA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SNTA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SNTA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SNTA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SNTA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SNTA+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SNTA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SNTA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SNTA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SNTA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SNTA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SNTA/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SNTA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SNTA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SNTA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SNTA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SNTA
$SNTA DD Notes ~ http://www.ddnotesmaker.com/SNTA
Shows how thin we are moving up. That big of a jump in relatively low volume. Strong support at .22 and thin to .30
Almost a 200k buy a few minutes ago at the ask....
SNTA, give us something positive to help this PPS recover. Based on cash alone this should be trading higher.
Dipope, you are absolutely right!
Clearly shorting it down to ride it back up. Typical
That's clearly not the best way to do your DD sylvia.
Saying "Someone said they read it" from a source (10K) that everyone can read (including you) doesn't count as doing your research. That's sort of equivalent to reporting a rumor based on a provable fact and as such isn't worth much since it is all based on unsubstantiated hearsay that can be either proven True or False as it is totally dependent on facts that are readily available to all.
Best to you and all Longs. dp
Cramerica, I don't know I read it on stockwits someone claim they read on 10-k!
Temporarily .22s
Another rough day. Where is the bottom???
Cash and cash assets are still strong. Lots of red last 2 days but I will continue to hold.
Somebody must have been tipped off 2 days ago with 7 million volume
I wouldn't count on it, management hasn't made any guarantees.
Read on stockwits, snta was closing up shop and shareholders are getting 60 cents per share.
Aside from the remaining cash on hand, there are only 2 potential catalysts left here. And at this point I think management will say just about anything to keep the share price intact, so I wouldn't count on the remaining cash being distributed to shareholders any time soon. This may be a good time to Abandon ship m8's
RIP SNTA
http://stks.co/g48PT <--- Most recent 10-K (PDF format)
Followers
|
40
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1877
|
Created
|
08/04/07
|
Type
|
Free
|
Moderators |
WEBSITE: http://www.syntapharma.com/ |
Total cash, cash equivalents and marketable securities is $88,241,000. Cash for cash pps should be 0.64. Read article here: http://www.bizjournals.com/boston/blog/bioflash/2016/02/two-local-biotechs-that-are-now-valued-lower-than.html?ana=yahoo $885M deal with GlaxoSmithKline (GSK) http://ir.syntapharma.com/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1235544 "Synta Pharmaceuticals Corp. currently has an average rating of “Hold” and a consensus price target of $2.56." http://www.wkrb13.com/markets/1144940/synta-pharmaceuticals-corp-snta-stake-increased-by-jennison-associates/ KEY FINANCIAL STATS: http://finance.yahoo.com/q/ks?s=SNTA |
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs that address severe medical conditions, including cancer and chronic inflammatory diseases. The company's product pipeline primarily includes elesclomol, an oxidative stress inducer, which is in Phase III clinical trial for the treatment of metastatic melanoma, and about to enter Phase II clinical trial for the treatment of additional cancers. It also develops STA-9090, an Hsp90 inhibitor, which is in the Phase I clinical trial for the treatment of cancer; and STA-9584, which is in preclinical development stage for the treatment of cancer. In addition, the company offers Apilimod (STA-5326), which is in Phase IIa clinical trial in patients with rheumatoid arthritis, as well as sponsors a Phase IIa clinical trial in patients with gastrointestinal manifestations of common variable immunodeficiency. Further, it provides Oral CRAC ion channel inhibitor program, which is in the lead optimization stage for the treatment of autoimmune diseases. The company has a partnership agreement with Glaxosmithkline for the development and commercialization of elesclomol; and a strategic alliance with Roche Holding AG to discover, develop, and commercialize small-molecule drugs targeting a novel family of ion channels. Synta Pharmaceuticals Corp. was founded in 2000 and is based in Lexington, Mass. CLINICAL TRIALS (10 of them): http://www.syntapharma.com/clinical-trials.php SHARE STRUCTURE: Outstanding Shares: 136.44M Float: 55M http://www.reuters.com/finance/stocks/overview?symbol=SNTA.OQ Institutional Investors hold 49.2% of outstanding shares Huge institutional names own SNTA including: Morgan Stanley Goldman Sachs BNP ParisBas Charles Schwab BlackRock Deutsche Bank Wells Fargo Credit Suisse CitiGroup Royal Bank of Canada Vanguard Group Caxton Corp Jacobs Levy Barclays PLC Swiss National Bank Jacobs Levy Panagora Nomura Holdings ...and many more! http://www.nasdaq.com/symbol/snta/institutional-holdings Insider Buying: http://www.form4oracle.com/company/synta-pharmaceuticals-corp-snta/company-transactions?id=11624 CHARTS: |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |